Drugs / Darlifarnib
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06026410 | Oct 2023 → Jan 2027 expected | clear cell renal carcinoma, colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Kura Oncology, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Darlifarnib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06026410 ↗ |
| Action | Inhibit | “a farnesyltransferase inhibitor (FTI)” NCT06026410 ↗ |
| Route | Oral | “Oral administration” NCT06026410 ↗ |